Blockade Medical Announces FDA Clearance and CE Mark Approval of Additions to the Barricade Coil System

March 4, 2014—Blockade Medical LLC (Irvine, CA), a developer of catheter-based therapeutic devices for the treatment of cerebral aneurysms, announced two additions to the company’s Barricade coil system: an enhanced framing coil and a complex finishing coil. These products have received 510(k) clearance from the US Food and Drug Administration (FDA) and are European CE Mark approved.

According to Blockade Medical, the endovascular Barricade coil system is an embolization coil line that is designed to occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels. The system is a comprehensive bare platinum coil line available in framing, filling, and finishing shapes. The device received CE Mark approval in July 2012 and FDA 510(k) clearance in March 2013.

“The enhanced first loop design of the new Barricade framing coil will expand the types of aneurysms I can now treat with the Barricade coil system,” commented Adnan Siddiqui, MD, in the company’s press release. Dr. Siddiqui is Vice-Chairman and Associate Professor of the Department of Neurosurgery at the State University of New York, Buffalo.

“In my clinical experience, the existing Barricade finishing coil delivers best in class softness and deliverability from a helical finishing coil. The new complex finishing coil should provide even more effective finishing of aneurysms due to its unique shape and is a clinically relevant addition to the product line,” added Spiros Blackburn, MD, who is Assistant Professor of Neurosurgery at the University of Florida College of Medicine in Gainesville, Florida.